Anticoagulation of Systemic Sclerosis Patients In Question PDF Print E-mail
Saturday, 18 May 2013 23:43
Australia is in a state of ‘clinical equipoise’ over whether to anticoagulate systemic sclerosis patients with pulmonary hypertension, experts say. And with observational studies showing the treatment is associated with a  fivefold reduction in mortality, the issue demanded a prompt resolution, the team of rheumatologists wrote in this week’s Internal Medicine Journal.

Describing the issue as one of the “most contentious” in the management of patients with connective tissue disease, the doctors said anticoagulation was currently not regarded as standard care in these patients.

A previous study conducted by the authors had revealed that warfarin was used in around 30% of patients, with no Australian centres routinely anticoagulating patients. Practice also varied internationally, they said.

Acknowledging that systemic sclerosis patients had specific bleeding risks that made INR monitoring challenging, the authors said the recent advent of orally administered Xa inhibitors could overcome some of these issues.

“The preliminary evidence favouring a survival benefit with anticoagulation administered in conjunction with PAH-specific therapy makes a compelling case for evaluating its therapeutic efficacy in SSc-PAH,” the study authors wrote.

The authors called for a randomised controlled trial, arguing that a placebo arm was ethically justifiable because of uncertainty around the benefits and relative risks. “The substantially shortened life expectancy of patients with SSc-PAH further adds an element of urgency to the need to resolve this contentious issue,” they added.

Source: Rheumatology Update (2013), "Anticoagulant conundrum for PAH sclerosis"; original article can be viewed here.

 
More articles :

» Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants

Systemic sclerosis is a multisystem, connective tissue disease of unknown aetiology characterized by vascular dysfunction, autoimmunity, and enhanced fibroblast activity resulting in fibrosis of the skin, heart, and lungs, and ultimately internal...

» The Scleroderma Foundation Teams Up with Traitwise

The has teamed up with Austin, TX company, Incorporated, to launch a unique survey to poll thousands of patients and their caregivers. Data from the survey will be shared with researchers nationally and internationally in an effort to improve...

» Unite Against Scleroderma 2012

{gallery}unite3{/gallery}

» 5 Things to Know About Raynaud’s

Having a chronic condition like Raynaud’s requires vigilance. Here are five things that you should know about your condition from rheumatologists who treat it.Stay warm. Wear gloves and mittens and heavy socks whenever you expect to be in a cold...

» Scleroderma in Children: Emerging Management Issues

Saumya PandaDepartment of Dermatology, KPC Medical College, Kolkata, IndiaDate of Web Publication: 21-Jul-2010Abstract         Scleroderma is a set of rare connective tissue diseases of unknown etiology. It is...

» Understanding Autoimmunity

What is Autoimmunity?One of the functions of the immune system is to protect the body by responding to invading microorganisms, such as viruses or bacteria, by producing antibodies or sensitized (types of white blood cells). Under normal...